Mirati's KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear

Mirati's KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear

Source: 
Fierce Pharma
snippet: 

Just as Amgen’s KRAS contender Lumakras suffered a sequential sales decline, Mirati Therapeutics’ rival drug Krazati has surprised analysts in its first full quarter on the market. But investors remain more interested in Mirati’s plan for newly diagnosed lung cancer patients.